M. Silverman

发表

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.

K. Behbakht, G. Ball, W. Huh, 2008, Gynecologic oncology.

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial.

N. Brünner, A. Berkenblit, U. Matulonis, 2005, Gynecologic oncology.

Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees

C. Tangen, KyungMann Kim, R. Freedman, 2006, Clinical trials.

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

G. Shapiro, E. Kwak, J. Yang, 2014, Investigational New Drugs.

Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.

K. Jacobson, P. Fishman, I. Avni, 2010, Ophthalmology.

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

P. Fishman, N. Lev-Cohain, Inbal Itzhak, 2021, Alimentary pharmacology & therapeutics.

Therapeutic Effect of Oral CF101 in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Phase II Study

Alex, P. Fishman, D. Bristol, 2014 .

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.

K. Garey, Chenlin Hu, B. Hanson, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults

L. Reynolds, M. Silverman, S. Duggan, 2022, The Journal of Prevention of Alzheimer's Disease.

Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.

P. Fishman, W. Carey, W. Kerns, 2004, International journal of clinical pharmacology and therapeutics.

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects

K. Garey, M. Alam, M. Ducharme, 2020, The Journal of antimicrobial chemotherapy.

Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections.

N. Brown, M. Silverman, Xianghong Yu, 2019, Bioorganic & medicinal chemistry.

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

P. Zarrinkar, J. Cortes, F. Giles, 2007 .

Abstract A89: A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors.

G. Shapiro, D. Cho, Chia‐Chi Lin, 2011 .

Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson

P. Fishman, Inbal Itzhak, Shira Cohen, 2018, Journal of immunology research.

Nitrous Oxide Self-Administered from a Demand Valve for 4-Minute Period: Dose-Effect on Attention, Mode and Wakefulness

J. Jakobsson, P. Blom, Royce S. Fishman, 2011 .

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection

K. Garey, Chenlin Hu, A. Gonzales-Luna, 2022, Antimicrobial agents and chemotherapy.

Safety and tolerability of two percent cyclosporine (Sandimmune) ophthalmic ointment in normal volunteers.

P. Nadler, M. Silverman, S. Solch, 1991, Journal of ocular pharmacology.

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Catriona Jamieson, Ayalew Tefferi, Moshe Talpaz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers

Jerome J. Schentag, R. Brown, D. Nix, 1990, Antimicrobial Agents and Chemotherapy.

Pilot Trial of Cyclosporine 1% Ophthalmic Ointment in the Treatment of Keratoconjunctivitis Sicca

M. O’connell, R. Laibovitz, M. Silverman, 1993, Cornea.

Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects

R. Brown, R. Stroshane, A. Boddy, 1990, Antimicrobial Agents and Chemotherapy.

ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial

Francisco A. R. Garcia, C. Crum, R. Urban, 2004, Obstetrics and gynecology.

A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.

D. Gilliland, J. Cortes, D. Gilliland, 2009 .

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

P. Fishman, T. Ciuleanu, A. Croitoru, 2021, Cancers.

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

V. Strand, P. Fishman, I. Rosner, 2008, The Journal of rheumatology.

Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform

Dean Ho, Theodore Kee, Peter Wang, 2018, Advanced Therapeutics.

Clinical Trials in Cervical Intraepithelial Neoplasia: Balancing the Need for Efficacy Data with Patient Safety

J. Weber, M. Hedley, K. Petry, 2002, Journal of lower genital tract disease.

Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

L. Akerman, M. Ziv, M. David, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis

J. Cortes, D. Gilliland, R. Stone, 2008 .

LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor

K. Garey, M. Ducharme, M. Kankam, 2019, Open Forum Infectious Diseases.

A Proposed New Classification of Skin and Soft Tissue Infections Modeled on the Subset of Diabetic Foot Infection

Benjamin A Lipsky, W. Joseph, M. Silverman, 2016, Open forum infectious diseases.

The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis

P. Fishman, W. Kerns, A. Ochaion, 2007, Expert opinion on investigational drugs.

Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.

P. Fishman, C. Giurcaneanu, M. Rotaru, 2016, Journal of drugs in dermatology : JDD.

Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis

G. Webster, M. Silverman, Alison M. Luckey, 2015, Multiple sclerosis journal - experimental, translational and clinical.

Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men.

S. Warrington, G. Lam, M. Silverman, 2004, International journal of clinical pharmacology and therapeutics.

CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

P. Fishman, R. Patoka, O. Benjaminov, 2012, The oncologist.

A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors

Y. Devary, O. Benjaminov, S. Stemmer, 2017, Molecular and clinical oncology.

Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects

P. Fishman, S. Stemmer, W. Kerns, 2023, Purinergic Signalling.

Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.

G. Ball, L. Piller, M. Silverman, 2011, Contemporary clinical trials.

Editorial: targeting aberrant hepatic inflammation for treatment of non‐alcoholic steatohepatitis—authors' reply

P. Fishman, N. Lev-Cohain, Inbal Itzhak, 2022, Alimentary Pharmacology and Therapeutics.

A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.

M. Robson, S. Domchek, S. Attwell, 2022, Journal of Clinical Oncology.